CAPTRUST Financial Advisors
VIR icon

CAPTRUST Financial Advisors’s Vir Biotechnology VIR Stock Holding History

CAPTRUST Financial Advisors’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$407K Buy
39,917
+2,362
+6% +$22.5K ﹤0.01% 2325
2026
Q1 		$336K Buy
37,555
+17,781
+90% +$142K ﹤0.01% 2312
2025
Q4 		$119K Buy
19,774
+672
+4% +$4K ﹤0.01% 2593
2025
Q3 		$109K Sell
19,102
-11,637
-38% -$59.5K ﹤0.01% 2500
2025
Q2 		$155K Buy
30,739
+8,739
+40% +$46.9K ﹤0.01% 2341
2025
Q1 		$143K Buy
22,000
+1,497
+7% +$13.3K ﹤0.01% 2208
2024
Q4 		$150K Buy
20,503
+4,683
+30% +$36.9K ﹤0.01% 2174
2024
Q3 		$118K Buy
+15,820
New +$137K ﹤0.01% 2193
2022
Q3 		– Sell
-1,823
Closed -$46K – 4004
2022
Q2 		$46K Buy
1,823
+1,690
+1,271% +$39.5K ﹤0.01% 2821
2022
Q1 		$3K Sell
133
-3
-2% -$89 ﹤0.01% 4395
2021
Q4 		$6K Buy
+136
New +$5.33K ﹤0.01% 4008
2021
Q1 		– Sell
-500
Closed -$13K – 4478
2020
Q4 		$13K Buy
+500
New +$16.3K ﹤0.01% 2464

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

CAPTRUST Financial Advisors's VIR Position: Q2 2026 in Review

CAPTRUST Financial Advisors increased its Vir Biotechnology (VIR) stake by 6.3% in Q2 2026, buying an estimated $22.5K and bringing the position to 39,917 shares worth $407K. The position accounts for ﹤0.01% of the portfolio, ranked #2325.

CAPTRUST Financial Advisors first reported a position in VIR in Q4 2020 and has held it in 12 quarters since. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • CAPTRUST Financial Advisors held 39,917 shares of Vir Biotechnology worth $407K as of Q2 2026.
  • CAPTRUST Financial Advisors bought 2,362 Vir Biotechnology shares in Q2 2026, an estimated $22.5K.
  • Vir Biotechnology made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q2 2026, its #2325 holding.
  • CAPTRUST Financial Advisors first reported a position in Vir Biotechnology in Q4 2020 and has held it in 12 quarters since.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.